Supplementary Online Content


eFigure 1. Flowchart of participants at enrollment and at follow-ups of the prospective ProgStar study
eFigure 2. Spaghetti plots of best corrected visual acuity (BCVA) (LogMAR) over the two years by baseline BCVA level
eFigure 3. Spaghetti plots of BCVA (LogMAR) over the two years by baseline fovea lesion involvement status.
eTable. Fovea involvement phenotype by best corrected visual acuity (BCVA) at baseline

This supplementary material has been provided by the authors to give readers additional information about their work.

© 2018 American Medical Association. All rights reserved.
**Table.** Fovea involvement phenotype by best corrected visual acuity (BCVA) at baseline.

<table>
<thead>
<tr>
<th>Baseline BCVA level</th>
<th>Normal AF N(%)</th>
<th>QDAF N(%)</th>
<th>Increased AF N(%)</th>
<th>DDAF N(%)</th>
<th>Total N(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>**No VI ***</td>
<td>8 (44.44)</td>
<td>6 (33.33)</td>
<td>2 (11.11)</td>
<td>2 (11.11)</td>
<td>18</td>
</tr>
<tr>
<td><strong>Mild VI</strong></td>
<td>25 (32.05)</td>
<td>38 (48.72)</td>
<td>4 (5.13)</td>
<td>11 (14.10)</td>
<td>78</td>
</tr>
<tr>
<td><strong>Moderate VI</strong></td>
<td>3 (1.23)</td>
<td>177 (72.54)</td>
<td>13 (5.33)</td>
<td>51 (20.90)</td>
<td>244</td>
</tr>
<tr>
<td><strong>Severe VI</strong></td>
<td>0 (0.00)</td>
<td>39 (36.45)</td>
<td>2 (1.87)</td>
<td>66 (61.68)</td>
<td>107</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>36 (44.7)</td>
<td>260 (58.7)</td>
<td>21 (4.7)</td>
<td>130 (29.1)</td>
<td>447</td>
</tr>
</tbody>
</table>

*No VI: VA better or equal to 20/25; Mild VI: VA worse than 20/25 to 20/70; Moderate VI: VA worse than 20/70 to 20/200; Severe VI/Blindness: VA worse than 20/200.
AF: autofluorescence. QDAF: questionably decreased AF. DDAF: definitely decreased AF.
89% of participants with both eyes enrolled

Baseline
259 participants enrolled*
n=489 study eyes

Month 6
238 (92%) participants
n=451 study eyes

Month 12
241 (93%) participants
n=456 study eyes

Month 18
230 (89%) participants
n=435 study eyes

Month 24
230 (89%) participants
n=434 study eyes

*207 participants (n=391 study eyes) attended all five visits; 29 participants (n=55 study eyes) attended the baseline and three follow-up visits; 10 participants (n=20 study eyes) attended the baseline and two follow-up visits; 4 participants (n=7 study eyes) attended the baseline and one follow-up visits; and 9 participants (n=16 study eyes) only attended the baseline visit. The longitudinal analysis using linear mixed effects models (LMMEM) utilized data from all available visits, including the visits from participants with missing visits.
eFigure 2. Spaghetti plots of best corrected visual acuity (BCVA) (LogMAR) over the two years by baseline BCVA level (each line shows data for one eye)
Figure 3. Spaghetti plots of BCVA (LogMAR) over the two years by baseline fovea lesion involvement status.